United States Anesthesia Drugs Market, By Type [General Inhalation Anesthesia, General Intravenous Anesthesia (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl) and Local Anesthesia (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine], Companies (Baxter International, Endo International plc, AbbVie & Others)
Anesthesia is a medicine which is given to relieve pain and sensation during surgery. Drugs render a patient unresponsive and unconscious. United States Anesthesia Drugs Market is projected to reach US$ 5 Billion by the year 2024 owing to the increasing prevalence of cardiovascular cases, rising geriatric population and growing number of urgent surgeries in the United States. The different types of anesthesia are Local Anesthesia, General Inhalation Anesthesia and General Intravenous Anesthesia. Local Anesthesia and General Anesthesia are the two commonly used types of anesthesia. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation. Furthermore, the public and private health insurers’ consideration of adding anesthetic products in their reimbursement policy is expected to boost the US anesthesia drugs market in the recent years.
All Major Companies Losing their Market Share
In United States all established companies are losing their market share. Primarily because anesthesia drugs are mostly sold in generic form as it is available in the low cost. The companies studied in the report are Baxter International Inc, Endo International plc & AbbVie. Today, with the help of anesthesia medical facilities, performs various surgeries to treat patient’s deformities in the field of trauma, cardiovascular, gastrointestinal, urological, orthopedics, ophthalmology, neurology, oncology and cosmetics.
Renub Research report titled “United States Anesthesia Drugs Market, By Type [General Inhalation Anesthesia, General Intravenous Anesthesia (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl) and Local Anesthesia (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine], Companies (Baxter International, Endo International plc, AbbVie & Others)” provides a complete analysis of United States Anesthesia Drugs Market.
By Type – General Intravenous Anesthesia leads the Market but Local Anesthesia Drugs is the Future
The report studies the market of the following Anesthesia Drugs segments: General Inhalation Anesthesia, General Intravenous Anesthesia can be further subdivided into (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl), Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs. Local Anesthesia is further segmented into (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine). Among these Articaine and Lidocaine have good market share.
Companies Analysis
Baxter International, Endo International plc, and AbbVie are some of the top companies operating in the United States Anesthesia Drugs Market; which has been studied thoroughly in the report.
This market research report provides a complete analysis of the United States Anesthesia Drugs Market and their projections for the upcoming years, Growth Drivers, Challenges, and Reimbursement policy.
By Type - United States Anesthesia Drugs Market
1. General Inhalation Anesthesia
2. General Intravenous Anesthesia
1. Baxter International Inc
2. Endo International plc
3. AbbVie
This Report provides the answer of following Questions:
All Major Companies Losing their Market Share
In United States all established companies are losing their market share. Primarily because anesthesia drugs are mostly sold in generic form as it is available in the low cost. The companies studied in the report are Baxter International Inc, Endo International plc & AbbVie. Today, with the help of anesthesia medical facilities, performs various surgeries to treat patient’s deformities in the field of trauma, cardiovascular, gastrointestinal, urological, orthopedics, ophthalmology, neurology, oncology and cosmetics.
Renub Research report titled “United States Anesthesia Drugs Market, By Type [General Inhalation Anesthesia, General Intravenous Anesthesia (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl) and Local Anesthesia (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine], Companies (Baxter International, Endo International plc, AbbVie & Others)” provides a complete analysis of United States Anesthesia Drugs Market.
By Type – General Intravenous Anesthesia leads the Market but Local Anesthesia Drugs is the Future
The report studies the market of the following Anesthesia Drugs segments: General Inhalation Anesthesia, General Intravenous Anesthesia can be further subdivided into (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl), Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs. Local Anesthesia is further segmented into (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine). Among these Articaine and Lidocaine have good market share.
Companies Analysis
Baxter International, Endo International plc, and AbbVie are some of the top companies operating in the United States Anesthesia Drugs Market; which has been studied thoroughly in the report.
This market research report provides a complete analysis of the United States Anesthesia Drugs Market and their projections for the upcoming years, Growth Drivers, Challenges, and Reimbursement policy.
By Type - United States Anesthesia Drugs Market
1. General Inhalation Anesthesia
2. General Intravenous Anesthesia
- Propofol
- Benzodiazepines Class
- Fospropofol Disodium
- Ketamine
- Methohexital Sodium
- Pentobarbital
- Etomidate
- Fentanyl
- Articaine
- Bupivacaine
- Lidocaine
- Mepivacaine
- Prilocaine
1. Baxter International Inc
2. Endo International plc
3. AbbVie
This Report provides the answer of following Questions:
- What will be the United States Anesthesia Drugs Market by 2024?
- What will be the United States Local Anesthesia Drugs Market for the year 2024?
- What was the United States General Inhalation Anesthesia Drugs Market in 2017?
- Among General Inhalation, General Intravenous and Local Anesthesia; which one is driving the United States Anesthesia Drugs Market?
- What are the key driving forces for United States Anesthesia Drugs Market?
- What are the key challenges to United States Anesthesia Drugs Market?
1. EXECUTIVE SUMMARY
2. UNITED STATES ANESTHESIA DRUGS MARKET
3. MARKET SHARE – UNITED STATES ANESTHESIA DRUGS
3.1 Anesthesia Drugs
3.2 General Intravenous Anesthesia Drugs
3.3 Local Anesthesia Drugs
3.4 Company
4. MARKET – UNITED STATES ANESTHESIA DRUGS TYPES
4.1 General Inhalation Anesthesia Drugs Market
4.2 General Intravenous Anesthesia Drugs Market
4.3 Local Anesthesia Drugs Market
5. MARKET – GENERAL INTRAVENOUS ANESTHESIA DRUGS
5.1 Propofol
5.2 Benzodiazepines Class (Diazepam and Midazolam)
5.3 Fospropofol Disodium
5.4 Ketamine
5.5 Methohexital Sodium
5.6 Pentobarbital
5.7 Etomidate
5.8 Fentanyl
6. MARKET – LOCAL ANESTHESIA DRUGS
6.1 Articaine
6.2 Bupivacaine
6.3 Lidocaine
6.4 Mepivacaine
6.5 Prilocaine
7. COMPANIES - UNITED STATES ANESTHESIA DRUGS MARKET
7.1 Baxter International Inc. Anesthesia Drugs Sales
7.2 Endo International plc Anesthesia Drugs Sales
7.3 AbbVie Anesthesia Drugs Sales
7.4 Other Companies Anesthetic Drugs Sales
8. MERGER & ACQUISITION (M&A) – UNITED STATES ANESTHESIA
9. REIMBURSEMENT POLICY - PRIVATE HEALTH INSURANCE PROVIDERS
9.1 Aetna International
9.2 Coventry Health Care
9.3 Anthem Blue Cross and Blue Shield
9.4 Blue Cross and Blue Shield of Texas
9.5 UnitedHealthcare
9.5.1 State Exceptions
10. REIMBURSEMENT POLICY – PUBLIC HEALTH INSURANCE PROVIDERS
10.1 Medicare
10.2 MDWise
11. GROWTH DRIVERS
11.1 Growing Demand for Anesthesia Service
11.2 Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States
12. CHALLENGES
12.1 Un-match Anesthesia Providers in United States
12.2 Shortage of Anesthesia Drugs in United States
2. UNITED STATES ANESTHESIA DRUGS MARKET
3. MARKET SHARE – UNITED STATES ANESTHESIA DRUGS
3.1 Anesthesia Drugs
3.2 General Intravenous Anesthesia Drugs
3.3 Local Anesthesia Drugs
3.4 Company
4. MARKET – UNITED STATES ANESTHESIA DRUGS TYPES
4.1 General Inhalation Anesthesia Drugs Market
4.2 General Intravenous Anesthesia Drugs Market
4.3 Local Anesthesia Drugs Market
5. MARKET – GENERAL INTRAVENOUS ANESTHESIA DRUGS
5.1 Propofol
5.2 Benzodiazepines Class (Diazepam and Midazolam)
5.3 Fospropofol Disodium
5.4 Ketamine
5.5 Methohexital Sodium
5.6 Pentobarbital
5.7 Etomidate
5.8 Fentanyl
6. MARKET – LOCAL ANESTHESIA DRUGS
6.1 Articaine
6.2 Bupivacaine
6.3 Lidocaine
6.4 Mepivacaine
6.5 Prilocaine
7. COMPANIES - UNITED STATES ANESTHESIA DRUGS MARKET
7.1 Baxter International Inc. Anesthesia Drugs Sales
7.2 Endo International plc Anesthesia Drugs Sales
7.3 AbbVie Anesthesia Drugs Sales
7.4 Other Companies Anesthetic Drugs Sales
8. MERGER & ACQUISITION (M&A) – UNITED STATES ANESTHESIA
9. REIMBURSEMENT POLICY - PRIVATE HEALTH INSURANCE PROVIDERS
9.1 Aetna International
9.2 Coventry Health Care
9.3 Anthem Blue Cross and Blue Shield
9.4 Blue Cross and Blue Shield of Texas
9.5 UnitedHealthcare
9.5.1 State Exceptions
10. REIMBURSEMENT POLICY – PUBLIC HEALTH INSURANCE PROVIDERS
10.1 Medicare
10.2 MDWise
11. GROWTH DRIVERS
11.1 Growing Demand for Anesthesia Service
11.2 Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States
12. CHALLENGES
12.1 Un-match Anesthesia Providers in United States
12.2 Shortage of Anesthesia Drugs in United States
LIST OF FIGURES:
Figure 2-1: United States – Anesthesia Drugs Market (Million US$), 2011 – 2017
Figure 2-2: United States – Forecast for Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 3-1: United States – Anesthesia Drugs Market Share by Type (Percent), 2011 – 2017
Figure 3-2: United States – Forecast for Anesthesia Drugs Market Share by Type (Percent), 2018 – 2024
Figure 3-3: United States – General Intravenous Anesthesia Drugs Market Share (Percent), 2011 – 2017
Figure 3-4: United States – Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2018 – 2024
Figure 3-5: United States – Local Anesthesia Drugs Market Share (Percent), 2011 – 2017
Figure 3-6: United States – Forecast for Local Anesthesia Drugs Market Share (Percent), 2018 – 2024
Figure 3-7: United States – Anesthesia Drugs Market Share by Company (Percent), 2011 – 2017
Figure 3-8: United States – Forecast for Anesthesia Drugs Market Share by Company (Percent), 2018 – 2024
Figure 4-1: United States – General Inhalation Anesthesia Drugs Market (Million US$), 2011-2017
Figure 4-2: United States – Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 4-3: United States – General Intravenous Anesthesia Drugs Market (Million US$), 2011 – 2017
Figure 4-4: United States – Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 4-5: United States – Local Anesthesia Drugs Market (Million US$), 2011-2017
Figure 4-6: United States – Forecast for Local Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 5-1: United States – Propofol Market (Million US$), 2011 – 2017
Figure 5-2: United States – Forecast for Propofol Market (Million US$), 2018 – 2024
Figure 5-3: United States – Benzodiazepines Class Market (Million US$), 2011 – 2017
Figure 5-4: United States – Forecast for Benzodiazepines Class Market (Million US$), 2018 – 2024
Figure 5-5: United States – Fospropofol Disodium Market (Million US$), 2011 – 2017
Figure 5-6: United States – Forecast for Fospropofol Disodium Market (Million US$), 2018 – 2024
Figure 5-7: United States – Ketamine Market (Million US$), 2011 – 2017
Figure 5-8: United States – Forecast for Ketamine Market (Million US$), 2018 – 2024
Figure 5-9: United States – Methohexital Sodium Market (Million US$), 2011 – 2017
Figure 5-10: United States – Forecast for Methohexital Sodium Market (Million US$), 2018 – 2024
Figure 5-11: United States – Pentobarbital Market (Million US$), 2011 – 2017
Figure 5-12: United States – Forecast for Pentobarbital Market (Million US$), 2018 – 2024
Figure 5-13: United States – Etomidate Market (Million US$), 2011 – 2017
Figure 5-14: United States – Forecast for Etomidate Market (Million US$), 2018 – 2024
Figure 5-15: United States – Fentanyl Market (Million US$), 2011 – 2017
Figure 5-16: United States – Forecast for Fentanyl Market (Million US$), 2018 – 2024
Figure 6-1: United States – Articaine Market (Million US$), 2011-2017
Figure 6-2: United States – Forecast for Articaine Market (Million US$), 2018 – 2024
Figure 6-3: United States – Bupivacaine Market (Million US$), 2011-2017
Figure 6-4: United States – Forecast for Bupivacaine Market (Million US$), 2018 – 2024
Figure 6-5: United States – Lidocaine Market (Million US$), 2011-2017
Figure 6-6: United States – Forecast for Lidocaine Market (Million US$), 2018 – 2024
Figure 6-7: United States – Mepivacaine Market (Million US$), 2011-2017
Figure 6-8: United States – Forecast for Mepivacaine Market (Million US$), 2018 – 2024
Figure 6-9: United States – Prilocaine Market (Million US$), 2011-2017
Figure 6-10: United States – Forecast for Prilocaine Market (Million US$), 2018 – 2024
Figure 7-1: United States – Baxter International Anesthesia Drugs Sales (Million US$), 2011-2017
Figure 7-2: United States – Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-3: United States – Endo International plc Anesthesia Drugs Sales (Million US$), 2011-2017
Figure 7-4: United States – Forecast for Endo International plc Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-5: United States – AbbVie Anesthesia Drugs Sales (Million US$), 2011 - 2017
Figure 7-6: United States – Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-7: United States – Other Companies Anesthesia Drugs Sales (Million US$), 2011 – 2017
Figure 7-8: United States – Forecast for Other Companies Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 11-1: United States – Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
Figure 11-2: United States – Ageing Population by Age Group (Thousand), 2012 – 2016
Figure 12-1: United States – By Region Availability of Anesthesia Specialists (Percent), 2010
Figure 12-2: United States – By States Availability of Anesthesia Specialists (Percent), 2010
Figure 12-3: United States – Drugs Shortage (Number), 2001-2015
Figure 12-4: United States – Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012
Figure 2-1: United States – Anesthesia Drugs Market (Million US$), 2011 – 2017
Figure 2-2: United States – Forecast for Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 3-1: United States – Anesthesia Drugs Market Share by Type (Percent), 2011 – 2017
Figure 3-2: United States – Forecast for Anesthesia Drugs Market Share by Type (Percent), 2018 – 2024
Figure 3-3: United States – General Intravenous Anesthesia Drugs Market Share (Percent), 2011 – 2017
Figure 3-4: United States – Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2018 – 2024
Figure 3-5: United States – Local Anesthesia Drugs Market Share (Percent), 2011 – 2017
Figure 3-6: United States – Forecast for Local Anesthesia Drugs Market Share (Percent), 2018 – 2024
Figure 3-7: United States – Anesthesia Drugs Market Share by Company (Percent), 2011 – 2017
Figure 3-8: United States – Forecast for Anesthesia Drugs Market Share by Company (Percent), 2018 – 2024
Figure 4-1: United States – General Inhalation Anesthesia Drugs Market (Million US$), 2011-2017
Figure 4-2: United States – Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 4-3: United States – General Intravenous Anesthesia Drugs Market (Million US$), 2011 – 2017
Figure 4-4: United States – Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 4-5: United States – Local Anesthesia Drugs Market (Million US$), 2011-2017
Figure 4-6: United States – Forecast for Local Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 5-1: United States – Propofol Market (Million US$), 2011 – 2017
Figure 5-2: United States – Forecast for Propofol Market (Million US$), 2018 – 2024
Figure 5-3: United States – Benzodiazepines Class Market (Million US$), 2011 – 2017
Figure 5-4: United States – Forecast for Benzodiazepines Class Market (Million US$), 2018 – 2024
Figure 5-5: United States – Fospropofol Disodium Market (Million US$), 2011 – 2017
Figure 5-6: United States – Forecast for Fospropofol Disodium Market (Million US$), 2018 – 2024
Figure 5-7: United States – Ketamine Market (Million US$), 2011 – 2017
Figure 5-8: United States – Forecast for Ketamine Market (Million US$), 2018 – 2024
Figure 5-9: United States – Methohexital Sodium Market (Million US$), 2011 – 2017
Figure 5-10: United States – Forecast for Methohexital Sodium Market (Million US$), 2018 – 2024
Figure 5-11: United States – Pentobarbital Market (Million US$), 2011 – 2017
Figure 5-12: United States – Forecast for Pentobarbital Market (Million US$), 2018 – 2024
Figure 5-13: United States – Etomidate Market (Million US$), 2011 – 2017
Figure 5-14: United States – Forecast for Etomidate Market (Million US$), 2018 – 2024
Figure 5-15: United States – Fentanyl Market (Million US$), 2011 – 2017
Figure 5-16: United States – Forecast for Fentanyl Market (Million US$), 2018 – 2024
Figure 6-1: United States – Articaine Market (Million US$), 2011-2017
Figure 6-2: United States – Forecast for Articaine Market (Million US$), 2018 – 2024
Figure 6-3: United States – Bupivacaine Market (Million US$), 2011-2017
Figure 6-4: United States – Forecast for Bupivacaine Market (Million US$), 2018 – 2024
Figure 6-5: United States – Lidocaine Market (Million US$), 2011-2017
Figure 6-6: United States – Forecast for Lidocaine Market (Million US$), 2018 – 2024
Figure 6-7: United States – Mepivacaine Market (Million US$), 2011-2017
Figure 6-8: United States – Forecast for Mepivacaine Market (Million US$), 2018 – 2024
Figure 6-9: United States – Prilocaine Market (Million US$), 2011-2017
Figure 6-10: United States – Forecast for Prilocaine Market (Million US$), 2018 – 2024
Figure 7-1: United States – Baxter International Anesthesia Drugs Sales (Million US$), 2011-2017
Figure 7-2: United States – Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-3: United States – Endo International plc Anesthesia Drugs Sales (Million US$), 2011-2017
Figure 7-4: United States – Forecast for Endo International plc Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-5: United States – AbbVie Anesthesia Drugs Sales (Million US$), 2011 - 2017
Figure 7-6: United States – Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-7: United States – Other Companies Anesthesia Drugs Sales (Million US$), 2011 – 2017
Figure 7-8: United States – Forecast for Other Companies Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 11-1: United States – Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
Figure 11-2: United States – Ageing Population by Age Group (Thousand), 2012 – 2016
Figure 12-1: United States – By Region Availability of Anesthesia Specialists (Percent), 2010
Figure 12-2: United States – By States Availability of Anesthesia Specialists (Percent), 2010
Figure 12-3: United States – Drugs Shortage (Number), 2001-2015
Figure 12-4: United States – Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012
LIST OF TABLES:
Table 8-1: United States – Anesthesia Market Merger & Acquisitions (M&A), Jan 2016 – March 2017
Table 9-1: Coventry Health Care - Anesthesia Modifiers, 2016
Table 9-2: Blue Cross and Blue Shield of Texas - Physical Status Modifiers, 2017
Table 9-3: Blue Cross and Blue Shield of Texas - Qualifying Circumstances, 2017
Table 9-4: Blue Cross and Blue Shield of Texas - Modifier Information Billed by an Anesthesiologist, 2017
Table 9-5: Blue Cross and Blue Shield of Texas - Modifier Information Billed by a CRNA, 2017
Table 9-6: Blue Cross and Blue Shield of Texas - Anesthesia Modifier Reimbursement
Table 9-7: UnitedHealthcare Community – Modifiers, 2017
Table 10-1: Medicare - Reimbursement Formulas
Table 10-2: Medicare - General and Monitored Anesthesia Care
Table 10-3: Medicare - Anesthesia Modifiers, 2017
Table 10-4: MDwise –Type of Service & PA Requirement
Table 10-5: MDwise - Anesthesia Time Table, 2017
Table 10-6: MDwise - Qualifying Circumstances, 2017
Table 10-7: MDwise - Status Modifiers, 2017
Table 11-1: United States – Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030
Table 8-1: United States – Anesthesia Market Merger & Acquisitions (M&A), Jan 2016 – March 2017
Table 9-1: Coventry Health Care - Anesthesia Modifiers, 2016
Table 9-2: Blue Cross and Blue Shield of Texas - Physical Status Modifiers, 2017
Table 9-3: Blue Cross and Blue Shield of Texas - Qualifying Circumstances, 2017
Table 9-4: Blue Cross and Blue Shield of Texas - Modifier Information Billed by an Anesthesiologist, 2017
Table 9-5: Blue Cross and Blue Shield of Texas - Modifier Information Billed by a CRNA, 2017
Table 9-6: Blue Cross and Blue Shield of Texas - Anesthesia Modifier Reimbursement
Table 9-7: UnitedHealthcare Community – Modifiers, 2017
Table 10-1: Medicare - Reimbursement Formulas
Table 10-2: Medicare - General and Monitored Anesthesia Care
Table 10-3: Medicare - Anesthesia Modifiers, 2017
Table 10-4: MDwise –Type of Service & PA Requirement
Table 10-5: MDwise - Anesthesia Time Table, 2017
Table 10-6: MDwise - Qualifying Circumstances, 2017
Table 10-7: MDwise - Status Modifiers, 2017
Table 11-1: United States – Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030
